Systematic approaches to toxicology in the zebrafish.
As the current paradigms of drug discovery evolve, it has become clear that a more comprehensive understanding of the interactions between small molecules and organismal biology will be vital. The zebrafish is emerging as a complement to existing in vitro technologies and established preclinical in vivo models that can be scaled for high-throughput. In this review, we highlight the current status of zebrafish toxicology studies, identify potential future niches for the model in the drug development pipeline, and define the hurdles that must be overcome as zebrafish technologies are refined for systematic toxicology.
Harvard Medical School, Massachusetts General Hospital, and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Randall T
RT
Peterson
Calum A
CA
Macrae
D000818:Animals; D015197:Carcinogenicity Tests; D016503:Drug Delivery Systems; D015195:Drug Design; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D041981:Gastrointestinal Tract / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D023421:Models, Animal; D009132:Muscles / Q000187:drug effects; D009474:Neurons / Q000187:drug effects; D004364:Pharmaceutical Preparations; D010599:Pharmacokinetics; D010641:Phenotype; D018675:Toxicity Tests; D015027:Zebrafish
D004364:Pharmaceutical Preparations